Chalcone-based inhibitors against hypoxia-inducible factor 1—Structure activity relationship studies
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (1), 555-557
- https://doi.org/10.1016/j.bmcl.2010.10.063
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute
This publication has 18 references indexed in Scilit:
- Cancer Chemopreventive Activity and Metabolism of Isoliquiritigenin, a Compound Found in LicoriceCancer Prevention Research, 2010
- Natural compounds and the hypoxia-inducible factor (HIF) signalling pathwayBiochimie, 2009
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- Structure−Activity Relationship Studies of Chalcone Leading to 3-Hydroxy-4,3′,4′,5′-tetramethoxychalcone and Its Analogues as Potent Nuclear Factor κB Inhibitors and Their Anticancer ActivitiesJournal of Medicinal Chemistry, 2009
- A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivoglioblastoma modelsBMC Cancer, 2009
- Hypoxia-Inducible Factor-1 Inhibitory Benzofurans and Chalcone-Derived Diels−Alder Adducts from Morus SpeciesJournal of Natural Products, 2008
- Evaluation of HIF-1 inhibitors as anticancer agentsDrug Discovery Today, 2007
- NF‐κB SignalingAnnals of the New York Academy of Sciences, 2006
- Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouseInvestigational New Drugs, 2006
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003